Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: Responders versus nonresponders

European Respiratory Journal

Volumn 19, Issue 4, 2002, Pages 664-671

  Ghofrani, H A ^a   Wiedemann, R ^a   Rose, F ^a   Weissmann, N ^a   Schermuly, R T ^a   Quanz, K ^a   Grimminger, F ^a   Seeger, W ^a   Olschewski, H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Catheterization; Nitric oxide; Pulmonary hypertension; Second messenger; Swan Ganz

Indexed keywords

APROTININ; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; EDETIC ACID; GUANYLATE CYCLASE; KALLIKREIN; NITRIC OXIDE; OXYGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG RESPONSE; HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; PRIORITY JOURNAL; PROTEIN SECRETION; PROVOCATION TEST; PULMONARY HYPERTENSION; SWAN GANZ CATHETER; VASODILATATION;

ADMINISTRATION, INHALATION; ADULT; AGED; CASE-CONTROL STUDIES; CATHETERIZATION, SWAN-GANZ; CYCLIC GMP; HUMANS; HYPERTENSION, PULMONARY; LUNG; MIDDLE AGED; NITRIC OXIDE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0036206285     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00982001     Document Type: Article

References (30)

1. Primary pulmonary hypertension
2. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
3. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
4. Inhaled nitric oxide as a screening agent for safety identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
5. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange
6. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
7. Guanylyl cyclases and signaling by cyclic GMP
8. Cyclic GMP synthesis and function
9. Inhaled nitric oxide and nifedipine have similar effects on lung cGMP levels in rats
10. Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury
11. Urinary cGMP concentrations in severe primary pulmonary hypertension
12. Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans
13. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells
14. Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia
15. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion
16. Natriuretic peptides
17. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial
18. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
19. Role of pharmacologic tests in the treatment of primary pulmonary hypertension
20. Pulmonary hypertension
21. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
22. Atrial natriuretic peptide in primary pulmonary hypertension
23. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension
24. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension
25. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
26. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase
27. Activation of the cGMP-dependent protein kinase mimics the stimulatory effect of nitric oxide and cGMP on calcium-gated potassium channels
28. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message
29. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity